The DOI matches its Crossref record; the references it cites are not checked yet.
GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose
Open accessAbstract
Overeating and arrhythmic feeding promote obesity and diabetes. Glucagon-like peptide-1 receptor (GLP-1R) agonists are effective anti-obesity drugs but their use is limited by side effects. Here we show that oral administration of the non-calorie sweetener, rare sugar D-allulose (D-psicose), induces GLP-1 release, activates vagal afferent signaling, reduces food intake and promotes glucose tolerance in healthy and obese-diabetic animal models. Subchronic D-allulose administered at the light period (LP) onset ameliorates LP-specific hyperphagia, visceral obesity, and glucose intolerance. These effects are blunted by vagotomy or pharmacological GLP-1R blockade, and by genetic inactivation of GLP-1R signaling in whole body or selectively in vagal afferents. Our results identify D-allulose as prominent GLP-1 releaser that acts via vagal afferents to restrict feeding and hyperglycemia. Furthermore, when administered in a time-specific manner, chronic D-allulose corrects arrhythmic overeating, obesity and diabetes, suggesting that chronotherapeutic modulation of vagal afferent GLP-1R signaling may aid in treating metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









![Fig. 10 p.o. d-Allulose activates vagal afferents and NTS via GLP-1R. a–h Allu (1 g kg−1, p.o.), compared to saline, induced ERK1/2 phosphorylation in vagal afferent nodose ganglion (NG) (a–d) and medial NTS (e–h) in WT mice (n = 5) but not Glp1r KO mice (n = 6). Scale bar, 100 µm. i, j GLP-1 at 10−8 M increased [Ca2+]i in 6 of 74 (8.1%) single neurons isolated from nodose ganglion. Allu at 20 mM neither induced [Ca2+]i nor potentiated GLP-1-induced [Ca2+]i increases in nodose ganglion neurons. The trace in i was representative of six neurons. k–m Vagal afferent-specific Glp1r knockdown (KD) attenuated the anorexigenic effect of Allu (1 g kg−1, p.o.) in rats. Visualization of ZsGreen1 expression in the whole left NG of a rat injected with AAV9-Glp1r-shRNA particles (k). Relative expression of GLP-1 mRNA in the left NG (AAV injected), right NG (not injected) and hypothalamus in control and Glp1r KD rats (l). The cumulative food intake after Allu (1 g kg−1, p.o.) or saline administration in control and Glp1r KD rats fasted 16 h (m). n = 11. *p < 0.05 and **p < 0.01 by one-way ANOVA followed by Tukey’s test. Scale bar, 500 µm. n Proposed mechanism for the action of oral Allu. Acute Allu suppresses feeding and improves glucose tolerance via GLP-1-mediated vagal afferent pathway. When time-selectively administered, chronic d-allulose corrects arrhythmic overeating, obesity and diabetes, suggesting chronotherapeutic potential to enhance GLP-1R signaling to treat metabolic disorders. Error bars are SEM](https://figures.cochat.ai/paper-figures/f983e834db884f7a81aeec3fe33b5a5b/glp-1-release-and-vagal-afferent-activation-mediate-the-beneficial-metabolic-and-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, knockdown of GLP-1R in VANs increased meal size (39), and abolished the satiating effects of secretagogue-induced GLP-1 release (34).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 58 · Cited by 200
Metadata
- Authors
- Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., Hayakawa, M., Masuda, C., Okada, T., Hara, H., Drucker, D. J., Yamada, Y., Tokuda, M., & Yada, T.
- Affiliations
- Jichi Medical University (JP)
- Hokkaido University (JP)
- Akita University (JP)
- Nippon Medical School (JP)
- Mount Sinai Hospital (CA)
- Kagawa University (JP)
- Corresponding author
- Yada, Toshihiko
- ORCID
- Venue
- Nature Communications
- Published
- 2018-01-09
- Volume
- 9
- Issue
- 1
- Pages
- 113-113
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5760716
- OpenAlex
- W2781512269
- Cited by
- 200
- References
- 58
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 23 · 2023: 20 · 2022: 24 · 2021: 22 · 2020: 27 · 2019: 20 · 2018: 3
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) (submittedVersion, cc-by)
- Funders
- Japan Agency for Medical Research and Development (CREST, 2013-2017)
- Ministry of Education, Culture, Sports, Science and Technology (2011-2015, 2013−2017, 26670453, CREST)
- Jichi Medical University
- Novo Nordisk (154321)
- Japan Diabetes Foundation
- Canadian Institutes of Health Research (123391, 15432_1)
- Banting and Best Diabetes Centre, University of Toronto (154321)
- Japan Society for the Promotion of Science (16K15182, 15K09397, 26460302)
- Core Research for Evolutional Science and Technology (2011-2015)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Nursing › Nutrition and Dietetics › Biochemical Analysis and Sensing Techniques
- Keywords
- D-allulose, rare sugars, GLP-1 receptor, vagal afferents, chronotherapy, hyperphagia, obesity, diabetes mellitus, glucose tolerance, food intake regulation, vagotomy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Eating, Fructose, Hyperphagia, Male, Mice, Inbred C57BL, Obesity, Vagus Nerve, Rats, Wistar, Glucose Intolerance, Mice, Knockout, Anti-Obesity Agents, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. https://app.cochat.ai/papers/10.1038/s41467-017-02488-y
- The paper
- Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., Hayakawa, M., Masuda, C., Okada, T., Hara, H., Drucker, D. J., Yamada, Y., Tokuda, M., & Yada, T. (2018). GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nature Communications. https://doi.org/10.1038/s41467-017-02488-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.